Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization

Journal of Virology

Volumn 86, Issue 18, 2012, Pages 9929-9940

  Johnson, John B ^a   Lyles, Douglas S ^a   Alexander Miller, Martha A ^a   Parks, Griffith D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PROTEIN IC3B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN FUNCTION; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FEMALE; HUMAN; IN VITRO STUDY; MUMPS VIRUS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RESISTANCE;

ANIMALS; ANTIGENS, CD46; ANTIGENS, CD55; CHO CELLS; COMPLEMENT ACTIVATION; CRICETINAE; CRICETULUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICROSCOPY, IMMUNOELECTRON; MUMPS VIRUS; NEUTRALIZATION TESTS; VESICULOVIRUS; VIRUS ASSEMBLY;

MUMPS VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84866165001     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01154-12     Document Type: Article

References (48)

1. Ahmed M, Puckett S, Lyles DS. 2010. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther. 17: 883-892.
2. Atkinson JP, Liszewski MK, Richards A, Kavanagh D, Moulton EA. 2005. Hemolytic uremic syndrome: an example of insufficient complement regulation on self tissue. Ann. N. Y. Acad. Sci. 1056: 144-152.
3. Beebe DP, Cooper NR. 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126: 1562-1568.
4. Bernet J, Mullick J, Panse Y, Parab PB, Sahu A. 2004. Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b. J. Virol. 78: 9446-9457.
5. Blue CE, Spiller OB, Blackbourn DJ. 2004. The relevance of complement to virus biology. Virology 319: 176-184.
6. Bolger MS, et al. 2007. Complement levels and activity in the normal and LPS-injured lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L748-L759.
7. Brown EL, Lyles DS. 2005. Pseudotypes of vesicular stomatitis virus with CD4 formed by clustering of membrane microdomains during budding. J. Virol. 79: 7077-7086.
8. Carroll MC. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5: 981-986.
9. Cummings KL, Waggoner SN, Tacke R, Hahn YS. 2007. Role of complement in immune regulation and its exploitation by virus. Viral Immunol. 20: 505.
10. Delgado MF, Polack FP. 2004. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. Expert Rev. Vaccines 3: 693-700.
11. Devaux P, Christiansen D, Plumet S, Gerlier D. 2004. Cell surface activation of the alternative complement pathway by the fusion protein of measles virus. J. Gen. Virol. 85: 1665-1673.
12. Gainey MD, Manuse MJ, Parks GD. 2008. Hyperfusogenic F protein enhances oncolytic potency of an SV5 P/V mutant without compromising sensitivity to type I interferon. J. Virol. 82: 9369-9380.
13. Gerlier D, et al. 1994. Measles virus receptor properties are shared by several CD46 isoforms differing in extracellular regions and cytoplasmic tails. J. Gen. Virol. 75: 2163-2171.
14. Hirsch RL, Wolinsky JS, Winkelstein JA. 1986. Activation of the alteralternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity. Arch. Virol. 87: 181-190.
15. Jayasekara JP, Moseman EA, Carroll MC. 2007. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 81: 3487-3494.
16. Johnson JB, Capraro GA, Parks GD. 2008. Differential mechanisms of complement mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology 376: 112-123.
17. Johnson JB, Grant K, Parks GD. 2009. The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J. Virol. 83: 7602-7611.
18. Kemper C, Atkinson JP. 2007. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7: 9-18.
19. Kerr MA. 1980. The human complement system: assembly of the classical pathway C3 convertase. Biochem. J. 189: 173-181.
20. Kim DD, Song WC. 2006. Membrane complement regulatory proteins. Clin. Immunol. 118: 127-136.
21. Liszewski MK, Post TW, Atkinson JP. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9: 431-455.
22. Liszewski MK, Fang CJ, Atkinson JP. 2008. Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine 26(Suppl 8): I22-I27.
23. Lublin DM, Atkinson JP. 1989. Decay-accelerating factor: biochemistry, molecular biology and function. Annu. Rev. Immunol. 7: 35-58.
24. Markiewski MM, Lambris JD. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727.
25. McSharry JJ, Pickering RJ, Caliguiri LA. 1981. Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology 114: 507-515.
26. Medof ME, Kinoshita T, Nussenzweig V. 1984. Inhibition of complement activation on the surface of cells after incorporation of decayaccelerating factor (DAF) into their membranes. J. Exp. Med. 160: 1558-1578.
27. Mills BJ, Beebe DP, Cooper NR. 1979. Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complementdependent viral lysis. J. Immunol. 123: 2518-2524.
28. Miyagawa S, et al. 2004. Delta-short consensus repeat 4-decay accelerating factor (DAF; CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis. J. Immunol. 173: 3945-3952.
29. Morrison TE, Fraser RJ, Smith PN, Mahalingam S, Heise MT. 2007. Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J. Virol. 81: 5132-5143.
30. Mullick J, et al. 2005. Identification of complement regulatory domains in vaccinia virus complement control protein. J. Virol. 79: 12382-12393.
31. Nayak S, Herzog RW. 2010. Progress and prospects: immune responses to viral vectors. Gene Ther. 17: 295-304.
32. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. 1982. Isolation of a human erythrocyte membrane glycoprotein with decayaccelerating activity for C3 convertases of the complement system. J. Immunol. 129: 184-189.
33. Okura E, et al. 2008. Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF. Xenotransplantation 15: 365-373.
34. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. 1983. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. U. S. A. 80: 5430-5434.
35. Post TW, Liszewski MK, Adams EM, Tedja I, Miller EA. 1991. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J. Exp. Med. 174: 93-102.
36. Roozendaal R, Carroll MC. 2006. Emerging patterns in complementmediated pathogen recognition. Cell 125: 29-32.
37. Russell SR, Sparrow RL, McKenzie IFC, Purcell DFJ. 1992. Tissuespecific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur. J. Immunol. 22: 1513-1518.
38. Saifuddin M, et al. 1997. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complementmediated destruction. J. Gen. Virol. 78: 1907-1911.
39. Schauber-Plewa C, Simmons A, Tuerk M, Pacheco C, Veres G. 2005. Regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther. 12: 238-245.
40. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. 2008. Cellular proteins in influenza virus particles. PLoS Pathog. 4: e1000085. doi:10.1371/journal.ppat.1000085.
41. Stoermer KA, Morrison TE. 2011. Complement and viral pathogenesis. Virology 411: 362-373.
42. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. 1996. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp. Med. 183: 307-310.
43. Stuart AD, Eustace HE, McKee TA, Brown TD. 2002. A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts. J. Virol. 76: 9307-9322.
44. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. 1998. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. U. S. A. 95: 7544-7549.
45. Vasantha S, et al. 1988. Interaction of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology 167: 433-441.
46. Veerhuis R, Nielsen HM, Tenner AJ. 2011. Complement in the brain. Mol. Immunol. 48: 1592-1603.
47. Welsh, RM, Jr. 1977. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. J. Immunol. 118: 348-354.
48. Zavada J. 1982. The pseudotype paradox. J. Gen. Virol. 63: 15-24.